Immunolocalization of BRCA1 protein in tumor breast tissue

Prescreening of BRCA1 mutation in Tunisian patients with hereditary breast cancer?

Wafa Troudi, N. Uhrhammer, K. Ben Romdhane, C. Sibille, W. Mahfoudh, Lotfi Chouchane, F. Ben Ayed, Y. J. Bignon, A. Ben Ammar Elgaaied

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

BRCA1 is a tumor suppressor gene which is inactivated by mutation in familial breast and ovarian cancers. Over 300 different disease causing germ-line mutations have been described; 60% are unique to an individual family. This diversity and the large size of the gene lead us to search for a pre-screening method for BRCA1 mutations. Since BRCA1 is a nuclear protein in normal cells, but reported by some authors to be cytoplasmic in breast tumor cells of patients with BRCA1 mutation, we evaluated immunohistochemistry as a prescreening technique to identify BRCA1 mutations in patients with familial presentation of breast cancer. Using a monoclonal antibody against the carboxy-terminal region of BRCA1, we performed immunohistochemistry on 18 tumor samples from patients with hereditary breast cancer. Cytoplasmic staining of BRCA1 was observed in 10 cases. Of the 18 tumors, 12 (66%) showed either BRCA mutation or BRCA1 accumulation or both, indicating that BRCA1 function might be lost in breast tumor cells not only through mutation, but also via abnormal cytoplasmic location. The immunohistochemical test used in this study would not be efficient as a pre-screening method of deleterious mutations, but it appeared useful to investigate tumor physiology.

Original languageEnglish
Pages (from-to)219-226
Number of pages8
JournalEuropean Journal of Histochemistry
Volume51
Issue number3
Publication statusPublished - Jul 2007
Externally publishedYes

Fingerprint

BRCA1 Protein
Breast Neoplasms
Mutation
Immunohistochemistry
Neoplasms
Germ-Line Mutation
Nuclear Proteins
Tumor Suppressor Genes
Ovarian Neoplasms
Monoclonal Antibodies
Staining and Labeling

Keywords

  • BRCA1
  • BRCA2
  • Breast cancer
  • DHPLC
  • Immunohistochemistry
  • Sequencing
  • Tunisian population

ASJC Scopus subject areas

  • Biophysics
  • Histology
  • Cell Biology

Cite this

Immunolocalization of BRCA1 protein in tumor breast tissue : Prescreening of BRCA1 mutation in Tunisian patients with hereditary breast cancer? / Troudi, Wafa; Uhrhammer, N.; Ben Romdhane, K.; Sibille, C.; Mahfoudh, W.; Chouchane, Lotfi; Ben Ayed, F.; Bignon, Y. J.; Ben Ammar Elgaaied, A.

In: European Journal of Histochemistry, Vol. 51, No. 3, 07.2007, p. 219-226.

Research output: Contribution to journalArticle

Troudi, W, Uhrhammer, N, Ben Romdhane, K, Sibille, C, Mahfoudh, W, Chouchane, L, Ben Ayed, F, Bignon, YJ & Ben Ammar Elgaaied, A 2007, 'Immunolocalization of BRCA1 protein in tumor breast tissue: Prescreening of BRCA1 mutation in Tunisian patients with hereditary breast cancer?', European Journal of Histochemistry, vol. 51, no. 3, pp. 219-226.
Troudi, Wafa ; Uhrhammer, N. ; Ben Romdhane, K. ; Sibille, C. ; Mahfoudh, W. ; Chouchane, Lotfi ; Ben Ayed, F. ; Bignon, Y. J. ; Ben Ammar Elgaaied, A. / Immunolocalization of BRCA1 protein in tumor breast tissue : Prescreening of BRCA1 mutation in Tunisian patients with hereditary breast cancer?. In: European Journal of Histochemistry. 2007 ; Vol. 51, No. 3. pp. 219-226.
@article{27b6c046c19640ecb752429cfd5327d7,
title = "Immunolocalization of BRCA1 protein in tumor breast tissue: Prescreening of BRCA1 mutation in Tunisian patients with hereditary breast cancer?",
abstract = "BRCA1 is a tumor suppressor gene which is inactivated by mutation in familial breast and ovarian cancers. Over 300 different disease causing germ-line mutations have been described; 60{\%} are unique to an individual family. This diversity and the large size of the gene lead us to search for a pre-screening method for BRCA1 mutations. Since BRCA1 is a nuclear protein in normal cells, but reported by some authors to be cytoplasmic in breast tumor cells of patients with BRCA1 mutation, we evaluated immunohistochemistry as a prescreening technique to identify BRCA1 mutations in patients with familial presentation of breast cancer. Using a monoclonal antibody against the carboxy-terminal region of BRCA1, we performed immunohistochemistry on 18 tumor samples from patients with hereditary breast cancer. Cytoplasmic staining of BRCA1 was observed in 10 cases. Of the 18 tumors, 12 (66{\%}) showed either BRCA mutation or BRCA1 accumulation or both, indicating that BRCA1 function might be lost in breast tumor cells not only through mutation, but also via abnormal cytoplasmic location. The immunohistochemical test used in this study would not be efficient as a pre-screening method of deleterious mutations, but it appeared useful to investigate tumor physiology.",
keywords = "BRCA1, BRCA2, Breast cancer, DHPLC, Immunohistochemistry, Sequencing, Tunisian population",
author = "Wafa Troudi and N. Uhrhammer and {Ben Romdhane}, K. and C. Sibille and W. Mahfoudh and Lotfi Chouchane and {Ben Ayed}, F. and Bignon, {Y. J.} and {Ben Ammar Elgaaied}, A.",
year = "2007",
month = "7",
language = "English",
volume = "51",
pages = "219--226",
journal = "European Journal of Histochemistry",
issn = "1121-760X",
publisher = "PagePress",
number = "3",

}

TY - JOUR

T1 - Immunolocalization of BRCA1 protein in tumor breast tissue

T2 - Prescreening of BRCA1 mutation in Tunisian patients with hereditary breast cancer?

AU - Troudi, Wafa

AU - Uhrhammer, N.

AU - Ben Romdhane, K.

AU - Sibille, C.

AU - Mahfoudh, W.

AU - Chouchane, Lotfi

AU - Ben Ayed, F.

AU - Bignon, Y. J.

AU - Ben Ammar Elgaaied, A.

PY - 2007/7

Y1 - 2007/7

N2 - BRCA1 is a tumor suppressor gene which is inactivated by mutation in familial breast and ovarian cancers. Over 300 different disease causing germ-line mutations have been described; 60% are unique to an individual family. This diversity and the large size of the gene lead us to search for a pre-screening method for BRCA1 mutations. Since BRCA1 is a nuclear protein in normal cells, but reported by some authors to be cytoplasmic in breast tumor cells of patients with BRCA1 mutation, we evaluated immunohistochemistry as a prescreening technique to identify BRCA1 mutations in patients with familial presentation of breast cancer. Using a monoclonal antibody against the carboxy-terminal region of BRCA1, we performed immunohistochemistry on 18 tumor samples from patients with hereditary breast cancer. Cytoplasmic staining of BRCA1 was observed in 10 cases. Of the 18 tumors, 12 (66%) showed either BRCA mutation or BRCA1 accumulation or both, indicating that BRCA1 function might be lost in breast tumor cells not only through mutation, but also via abnormal cytoplasmic location. The immunohistochemical test used in this study would not be efficient as a pre-screening method of deleterious mutations, but it appeared useful to investigate tumor physiology.

AB - BRCA1 is a tumor suppressor gene which is inactivated by mutation in familial breast and ovarian cancers. Over 300 different disease causing germ-line mutations have been described; 60% are unique to an individual family. This diversity and the large size of the gene lead us to search for a pre-screening method for BRCA1 mutations. Since BRCA1 is a nuclear protein in normal cells, but reported by some authors to be cytoplasmic in breast tumor cells of patients with BRCA1 mutation, we evaluated immunohistochemistry as a prescreening technique to identify BRCA1 mutations in patients with familial presentation of breast cancer. Using a monoclonal antibody against the carboxy-terminal region of BRCA1, we performed immunohistochemistry on 18 tumor samples from patients with hereditary breast cancer. Cytoplasmic staining of BRCA1 was observed in 10 cases. Of the 18 tumors, 12 (66%) showed either BRCA mutation or BRCA1 accumulation or both, indicating that BRCA1 function might be lost in breast tumor cells not only through mutation, but also via abnormal cytoplasmic location. The immunohistochemical test used in this study would not be efficient as a pre-screening method of deleterious mutations, but it appeared useful to investigate tumor physiology.

KW - BRCA1

KW - BRCA2

KW - Breast cancer

KW - DHPLC

KW - Immunohistochemistry

KW - Sequencing

KW - Tunisian population

UR - http://www.scopus.com/inward/record.url?scp=35748929094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35748929094&partnerID=8YFLogxK

M3 - Article

VL - 51

SP - 219

EP - 226

JO - European Journal of Histochemistry

JF - European Journal of Histochemistry

SN - 1121-760X

IS - 3

ER -